Back to All

Multi-Stakeholder Group Bring a unique economic solution to the Clinical Practice Gaps holding back Precision Medicine

19 March, 2024

Diaceutics PLC announce an open invitation to all stakeholders in precision medicine to join a landmark collaboration to address the economic barriers preventing patient access to life-changing precision medicines.   


The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum was established in 2023 to progress research undertaken by Diaceutics and The Personalized Medicine Coalition (PMC) which highlighted that 64.4% of a NSCLC patients in the US may not receive the best treatment for their disease. The globally recognised publication “The Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer” published in The Journal of Clinical Oncology Precision Oncology (JCO) in 2022, identified 7 Clinical Practice Gaps limiting patient access to precision medicine. 

In reaction to this critical finding, The Forum was established to urgently address the specific economic gaps limiting the advancement of precision medicine and to enable every patient to get the treatment they deserve. 

Co-chaired by Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, and Denny Van Liew, Board Member Emeritus at the PMC and veteran Solution Architect and Life Sciences Senior Advisor at Red Nucleus, The Forum is composed of leading experts in precision medicine across multiple stakeholders, each bringing extensive experience and insights from their careers. The shared aim is to provide the industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine. 

The solutions and recommendations proposed by the Forum will be shared and opened for discussion at a virtual global summit this May 1st. The highly anticipated summit provides a unique opportunity for all members of the precision medicine community to contribute to the culminating white paper recommendations and play a role in shaping the future of precision medicine. 

The Personalized Medicine Coalition has been a core partner both within the Clinical Practical Gaps research and The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum bringing strategic guidance. 

“The technologies, clinical practices, and financial incentives needed to successfully deliver high-quality health care in the era of personalised medicine differ substantially in comparison to what was needed during decades characterised by less sophisticated approaches.”  

said Daryl Pritchard, PMC’s Senior Vice President, Science Policy.  

“If the economic challenges providers face in adopting personalised medicine are left unaddressed, patients will suffer as high-value personalised medicine technologies will needlessly be left on the shelf.” 

Sarah Hersey, Vice President of Precision Medicine at Bristol-Myers Squibb and member of the Forum, expressed, 

 "This forum will serve as a healthy discourse to address the root complexities surrounding precision medicine and economic barriers. Together, the precision medicine community can identify possible solutions to close the clinical care gaps and help increase access to effective treatments for patients in need."  

Susanne reflects on the collective experience across the Forum members and shared patient-focused motivation,  

Those of us operating in precision medicine have been aware of the stealthy influence which economics have had on patient testing in precision medicine. This has not always been for the better. Revisiting the 2022 Clinical Practice Gaps research with a deeper focus on the economic barriers preventing patients receiving optimized targeted treatments has brought insightful discussion amongst the Forum members. It was rewarding to see how informed we all were on the real-world issues and how aligned we could be on the potential solutions to positively impact patients.” 


Denny Van Liew adds,  

“The passion amongst the Forum members demonstrates there is ambition to overcome the economic challenges which exist and support the wider precision medicine industry by providing practical recommendations and guidance on future policy development. I welcome everyone across precision medicine to join the discussion in May and to offer their input into this important paper.” 


The summit is already drawing attention from key industry leaders and influencers with a growing agenda of speakers and confirmed delegates. Secure your place and join the discussion. 

The summit is free to attend and open to all. To register please click the link below:   


The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum's activities are made possible by the dedicated efforts of the Forum members listed below and an educational grant from Diaceutics PLC.   

Forum Members 

Forum Member  


Amy Gorman 

Global Precision Medicine & Diagnostics Commercial Leader, AbbVie 

Brenda Yanak 

Founder, Clinical Transformation Partners 

Cecilia Schott 

VP, Head of Global Precision Diagnostics, Novartis 

Dawn Cardeiro 

Director of Precision Medicine, Point32Health 

Dr Daryl Pritchard  

Senior Vice President of Science Policy, Personalized Medicine Coalition 

Denny Van Liew 

Life Sciences Senior Advisor and Solution Architect, Red Nucleus 

Prof. Gerardine Doyle 


Full Professor of Accounting, University College Dublin 

Recently served a five-year term as Director of Michael Smurfit Graduate Business School  

Visiting Scholar, Harvard Business School 

Dr Kamala Maddali  


President, Health Collaborations, USA  

Prof. Mark Lawler 

Chair in Translational Cancer Genomics, Queen’s University Belfast 

Peter Keeling 

Founder, Diaceutics 

Dr Pranil Chandra  

Senior Vice President and Chief Genomics Officer, Pathgroup 

Sarah Hersey 

VP, Head of Precision Medicine, BMS  

Sibylle Lenz 

Head of Precision Medicine and Vice President, Merck & Co. Inc 

Susanne Munksted  

Chief Precision Medicine Officer, Diaceutics 

Terri Conneran 

Founder, KRAS Kickers 

Survivor of KRAS G12D lung cancer 



About the virtual summit 

Attendees at the summit will have exclusive access to a virtual conference hall hosting relevant economic papers analysed by Forum members along with gaining first access to a white paper summary of the Forum’s recommendations. The summit is free to attend and will consist of expert panel discussions with Forum members and the opportunity for direct Q&A and voting on key recommendations. 


Interested in becoming a sponsor or exhibiting at the hybrid summit? Contact [email protected]. 



[email protected] 


About Diaceutics  

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.   


We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.  


About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny